Details of the Drug
General Information of Drug (ID: DMJ0BEG)
| Drug Name |
AMIFLAMINE
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Amiflamine; UNII-NE25WV9C8S; 77518-07-1; NE25WV9C8S; 4-[(2S)-2-aminopropyl]-N,N,3-trimethylaniline; Amiflaminum; Amiflamina; Amiflamine [INN]; Amiflaminum [Latin]; Amiflamina [Spanish]; Astra FLA 336; (+)-FLA 336; AC1Q4TOK; AC1L2FRS; AC1Q29JB; ZINC915; SCHEMBL198456; CHEMBL3989773; DTXSID00228222; AKOS006272872; (+)-4-(dimethylamino)-; A,2-dimethylphenethylamine; (+)-4-(Dimethylamino)-alpha-2-dimethylphenethylamine; Benzeneethanamine, 4-(dimethylamino)-alpha,2-dimethyl-, (S); Benzeneethanamine, 4-(dimethylamino)-alpha,2-dimethyl-,
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 192.3 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.2 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


